MEDINFORM

Migration, Crosslink

📖

MEDINFORM

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-medinform

📖 Wiki Page

company2358 wordssynced 2026-04-02

Overview

flowchart TD companies_medinform["MEDINFORM"] style companies_medinform fill:#4fc3f7,stroke:#333,color:#000 companies_medinform_0["Market Position and Competitive Landscape"] companies_medinform -->|"includes"| companies_medinform_0 style companies_medinform_0 fill:#81c784,stroke:#333,color:#000 companies_medinform_1["Industry Context"] companies_medinform -->|"includes"| companies_medinform_1 style companies_medinform_1 fill:#ef5350,stroke:#333,color:#000 companies_medinform_2["Competitive Positioning"] companies_medinform -->|"includes"| companies_medinform_2 style companies_medinform_2 fill:#ffd54f,stroke:#333,color:#000 companies_medinform_3["Services and Capabilities"] companies_medinform -->|"includes"| companies_medinform_3 style companies_medinform_3 fill:#ce93d8,stroke:#333,color:#000 companies_medinform_4["Clinical Data Management"] companies_medinform -->|"includes"| companies_medinform_4 style companies_medinform_4 fill:#4fc3f7,stroke:#333,color:#000 companies_medinform_5["Biostatistics and Analytics"] companies_medinform -->|"includes"| companies_medinform_5 style companies_medinform_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

MEDINFORM is a specialized clinical data management and analytics company headquartered in Boston, Massachusetts, focused on supporting pharmaceutical research and clinical development for neurodegenerative diseases. Founded in 2005, the company provides comprehensive services spanning data management, biostatistics, regulatory submission support, and real-world evidence generation—capabilities that are particularly valuable for complex Alzheimer's disease, Parkinson's disease, and other neurodegenerative disease clinical programs.[@rwe_industry]

The company's niche focus on mid-market pharmaceutical and biotechnology companies distinguishes it from larger competitors like IQVIA and Optum that serve broad client bases.[@ehr_data] MEDINFORM's specialized expertise in neurodegenerative disease research, combined with deep knowledge of regulatory requirements and data standards, positions it as a valued partner for companies developing novel therapeutics for conditions with significant unmet medical need.

Market Position and Competitive Landscape

Industry Context

The pharmaceutical services industry has evolved significantly over the past two decades, with increasing reliance on specialized providers for clinical data management, analytics, and regulatory support. This evolution has been driven by:

Complexity of Modern Trials: Clinical trials, particularly in neurodegenerative diseases, involve increasingly complex data types including imaging, biomarkers, cognitive assessments, digital health measures, and real-world data from electronic health records and wearable devices.

Regulatory Requirements: FDA, EMA, and other regulatory agencies require sophisticated data management and analysis capabilities, with strict adherence to data standards (CDISC), electronic systems validation (21 CFR Part 11), and submission requirements.

Real-World Evidence: The growing importance of real-world evidence (RWE) in drug development has created demand for capabilities in electronic health record (EHR) data, claims data, patient registries, and other real-world data sources.

Cost Pressures: Pharmaceutical companies face pressure to reduce development costs and timelines, driving adoption of specialized service providers that can offer expertise and efficiency.

Competitive Positioning

| Company | Focus | Strengths | Limitations |
|---------|-------|-----------|-------------|
| MEDINFORM | Mid-market pharma & biotech, neurodegeneration | Specialized expertise, flexibility, competitive pricing | Smaller scale than major competitors |
| IQVIA | Broad pharmaceutical services | Global scale, extensive data assets | Less specialized focus |
| Optum | Healthcare analytics | EHR and claims data capabilities | Less clinical trial focus |
| Cegedim | Clinical trial services | Strong European presence | Limited US neurodegeneration focus |
| PRA Health Sciences | Clinical development | Full-service capabilities | Less specialized data services |

MEDINFORM's competitive differentiation derives from:

Specialized focus on neurodegenerative diseases
Expertise in Alzheimer's and Parkinson's disease clinical trials
Flexible, responsive service model
Competitive pricing for mid-market clients
Deep CDISC and regulatory expertise

Services and Capabilities

Clinical Data Management

Clinical data management represents MEDINFORM's core service offering, providing end-to-end support for clinical trial data collection, validation, and reporting:

Electronic Data Capture (EDC)

MEDINFORM implements and manages EDC systems using validated platforms that meet regulatory requirements. Services include:

Database design and build
Edit check programming
User acceptance testing
Data query management
Medical coding (ICD-10, MedDRA, SNOMED CT)
Integration with external data sources (lab, imaging, biomarker)

Modern EDC systems capture data from multiple sources including:
| Data Type | Collection Method | Standard Formats |
|-----------|------------------|------------------|
| Demographics | CRF entry | CDISC SDTM |
| Adverse Events | CRF entry + coding | MedDRA |
| Labs | Central lab transfer | CDISC SDTM |
| Imaging | DICOM transfer + analysis | NIfTI, DICOM |
| Biomarkers | Central lab transfer | Vendor-specific |
| PRO/eCOA | Device capture | CDISC SDTM |

CDISC Compliance

MEDINFORM maintains expertise in CDISC standards, providing:

SDTM (Study Data Tabulation Model) mapping and conversion
ADaM (Analysis Data Model) dataset creation
Define.xml documentation
CDISC certification for data submissions

This expertise is essential for FDA and EMA submissions, as regulatory agencies increasingly require CDISC-compliant data packages.

Data Validation

Rigorous data validation ensures data quality and integrity:

Edit checks and range validation
Cross-field consistency checks
Missing data identification
Protocol deviation detection
Source data verification support
Audit trail documentation

Biostatistics and Analytics

MEDINFORM provides comprehensive biostatistics services supporting clinical trial design, analysis, and reporting:

Statistical Analysis Plans (SAP)

Statistical Analysis Plans define the statistical methods for clinical trials:

Study design and sample size justification
Primary and secondary endpoint definitions
Statistical methodology and hypothesis testing
Handling of missing data and dropouts
Interim analysis specifications
Sensitivity analyses

Statistical Programming

Statistical programmers create analysis datasets and outputs:

ADaM dataset creation from SDTM data
Tables, figures, and listings (TFLs)
Integrated summaries (ISS/ISE)
Post-hoc and exploratory analyses
Modeling and simulation

Statistical Consulting

Statistical consultants provide expertise for:

Study design optimization
Endpoint selection and validation
Multiplicity adjustment
Bayesian analysis approaches
Adaptive trial design
Non-traditional endpoints (digital biomarkers)

Real-World Evidence

Real-world evidence generation has become increasingly important in drug development, and MEDINFORM offers capabilities in this growing area:

Observational Studies

MEDINFORM designs and executes observational studies:

Retrospective database studies
Prospective registry studies
Natural history studies
Comparative effectiveness research

Data Sources

| Source | Applications | Advantages | Limitations |
|--------|--------------|-------------|--------------|
| EHR Data | Disease progression, treatment patterns | Rich clinical data | Data quality variability |
| Claims Data | Healthcare utilization, costs | Large populations | Limited clinical detail |
| Patient Registries | Disease natural history | Structured data | Enrollment bias |
| PRO Platforms | Patient-reported outcomes | Direct patient input | Missing data |

Synthetic Control Arms

For rare diseases or conditions with high unmet need, MEDINFORM supports synthetic control arm approaches:

Historical control matching
External control arm construction
Bayesian borrowing methods
Regulatory strategy development

This approach can accelerate development in conditions where traditional placebo control is challenging.

Regulatory Support

MEDINFORM provides regulatory submission support services:

Electronic Submissions

eCTD (electronic Common Technical Document) preparation
Module 5 (clinical study reports) compilation
Regulatory database builds
Submission publishing and validation

Regulatory Consulting

Pre-IND/IND meeting preparation
NDA/BLA submission strategy
Regulatory pathway advice
Compliance consulting (21 CFR Part 11, GCP)

Post-Approval Studies

PASS/PAES design and execution
Label expansion studies
Phase 4 commitments
Publication support

Neurodegenerative Disease Specialization

Alzheimer's Disease Expertise

MEDINFORM has developed specialized capabilities for Alzheimer's disease clinical trials:

Cognitive Assessment Databases

Cognitive assessments are central to Alzheimer's disease clinical trials:
| Assessment | Description | Use in Trials |
|------------|-------------|---------------|
| MMSE | Mini-Mental State Examination | Screening, endpoint |
| MoCA | Montreal Cognitive Assessment | Screening, sensitive to MCI |
| CDR | Clinical Dementia Rating | Staging, global measure |
| ADAS-Cog | Alzheimer's Disease Assessment Scale-Cog | Primary endpoint |
| RBANS | Repeatable Battery for the Assessment of Neuropsychological Status | Cognitive domains |
| WCST | Wisconsin Card Sorting Test | Executive function |

MEDINFORM maintains databases specifically designed for cognitive assessments, including:

Normative data for interpretation
Longitudinal tracking capabilities
Multi-language support
Integration with cognitive testing platforms

Imaging Data Management

Neuroimaging is increasingly important in Alzheimer's disease trials:

MRI: hippocampal volume, cortical thickness, white matter hyperintensities
PET: amyloid (florbetapir, flutemetamol), tau (flortaucipir), FDG metabolism
CT: structural imaging, artifact assessment

MEDINFORM provides:

DICOM transfer and anonymization
Central reading coordination
Quantitative analysis data management
Imaging biomarker database development

Biomarker Data Management

Alzheimer's disease biomarkers are critical for patient selection and endpoint assessment:
| Biomarker | Matrix | Use |
|-----------|--------|-----|
| Aβ42 | CSF | Diagnosis, enrollment |
| Total tau (t-tau) | CSF | Neurodegeneration marker |
| Phospho-tau (p-tau) | CSF | Specific for AD |
| Neurofilament light (NfL) | CSF, blood | Neurodegeneration |
| GFAP | Blood | Astrocyte activation |
| Aβ42/40 ratio | Plasma | Amyloid status |

MEDINFORM maintains specialized biomarker databases with:

Central laboratory integration
Cut-point management for enrollment
Longitudinal tracking
Correlation analysis capabilities

Parkinson's Disease Expertise

MEDINFORM supports Parkinson's disease clinical trials with:

Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) databases
DaTscan and other imaging data management
Wearable sensor data integration
Non-motor symptom assessments (SCOPA-PS, PDQ-39)

Amyotrophic Lateral Sclerosis (ALS)

ALS clinical trials require specialized capabilities:

ALSFRS-R database management
FVC and other pulmonary function data
Survival analysis support
Biomarker data (neurofilaments)

Technology Platform

Infrastructure

MEDINFORM operates on secure, validated infrastructure:

Cloud Platform

SOC 2 Type II certified
HIPAA compliant
GDPR ready
21 CFR Part 11 validated
Multi-region redundancy

Security Features

Role-based access control
Encryption at rest and in transit
Audit logging
Penetration testing
Vulnerability management

Analytics Tools

MEDINFORM utilizes industry-standard analytics platforms:

SAS for statistical analysis
R for advanced analytics and visualization
Python for data processing and machine learning
Tableau for interactive dashboards
Shiny for web applications

Integrations

The platform supports integration with:

EDC systems (MedNet, REDCap, Veeva Vault)
IVR/IWR systems
Lab information systems
Imaging systems
ePRO platforms
EHR systems

Quality and Compliance

Certifications and Standards

MEDINFORM maintains compliance with industry standards:

| Standard | Application | Status |
|----------|-------------|--------|
| CDISC Certified | Data standards | Certified |
| ISO 27001 | Information security | Certified |
| SOC 2 Type II | Security, availability | Certified |
| HIPAA | Data privacy | Compliant |
| GDPR | EU data protection | Compliant |
| 21 CFR Part 11 | Electronic records | Validated |
| ICH-GCP | Clinical trial conduct | Compliant |

Quality Management

Quality is integrated throughout operations:

Standard operating procedures (SOPs)
Work instructions (WIs)
Training programs
Document control
Deviation management
CAPA processes
Periodic quality reviews

Clientele and Case Studies

Typical Clients

MEDINFORM serves clients including:

Mid-size pharmaceutical companies
Biotechnology companies
Academic research organizations
Foundation-funded research
Virtual/integrated biotech companies

Project Examples

Example 1: Phase 2 AD Trial

Multi-site international trial in early AD
400 patients across 50 sites
Cognitive and biomarker endpoints
CDISC-compliant database with integrated imaging and biomarker data

Example 2: Parkinson's Disease Registry

Natural history study in PD
2,000 patients across 20 sites
5-year follow-up
EHR integration for real-world data collection

Example 3: ALS Compassionate Use

Expanded access program support
Real-world data collection
Publication and regulatory reporting

Future Directions

Growth Areas

MEDINFORM is expanding capabilities in several areas:

Digital Health Integration

Wearable device data management
Digital biomarker platforms
Remote monitoring systems
AI/ML model validation

Decentralized Trials

Virtual trial support
Direct-to-patient enrollment
Telemedicine integration
Home health coordination

Advanced Analytics

Predictive modeling
Precision medicine support
Digital twin approaches
Causal inference methods

Technology Investment

Ongoing technology investments include:

Cloud infrastructure enhancement
AI/ML platform development
Data visualization improvements
Security infrastructure upgrades

Conclusion

MEDINFORM occupies an important niche in the pharmaceutical services landscape, providing specialized clinical data management and analytics services for neurodegenerative disease research. The company's focus on mid-market pharmaceutical and biotechnology companies, combined with deep expertise in Alzheimer's disease, Parkinson's disease, and related conditions, positions it as a valuable partner for clients developing novel therapeutics for these challenging conditions.

The company's comprehensive service offerings—spanning data management, biostatistics, real-world evidence, and regulatory support—provide clients with integrated solutions that meet the complex requirements of modern neurodegenerative disease clinical trials. Strong compliance and quality practices ensure that data meets regulatory standards, while specialized capabilities in cognitive assessments, imaging, and biomarkers address the unique needs of neurodegeneration research.

As the pharmaceutical industry continues to evolve, with increasing emphasis on real-world evidence, digital health, and precision medicine approaches, MEDINFORM is positioned to serve clients seeking specialized expertise in these areas. The company's focus on neurodegenerative diseases—where significant unmet medical need continues to drive active research and development—provides a stable foundation for continued growth and differentiation.

External Links

[MEDINFORM Official Website](https://www.medinform.com)](/companies/medinform)
[MEDINFORM Solutions](https://www.medinform.com/solutions)](/companies/medinform)
[CDISC Standards](https://www.cdisc.org/)
[FDA Data Standards](https://www.fda.gov/)
[21 CFR Part 11](https://www.accessdata.fda.gov/)
[HIPAA Guidance](https://www.hhs.gov/hipaa/)
[GDPR Information](https://gdpr.eu/)

References

[MEDINFORM Official Website](https://www.medinform.com)

[MEDINFORM Solutions](https://www.medinform.com/solutions)

[Clinical Data Interchange Standards Consortium - SDTM](https://www.cdisc.org/standards/foundational/sdtm)

[Clinical Data Interchange Standards Consortium - ADaM](https://www.cdisc.org/standards/foundational/adam)

[FDA Real-World Evidence Framework](https://www.fda.gov/science-research/science-research-and-collaboration-outreach-and-fda-science-workforce-initiatives/real-world-evidence-framework)

[Aisen PS, et al. Alzheimer's Disease Neuroimaging Initiative: progress and lessons learned. Alzheimers Dement. 2023;19(5):37254998](https://pubmed.ncbi.nlm.nih.gov/37254998/)

[Blennow K, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2020;16(10):601-614](https://pubmed.ncbi.nlm.nih.gov/32133291/)

[Zhou W, et al. Real-world evidence in neurodegenerative disease research. Nat Rev Neurol. 2022;18(8):35854102](https://pubmed.ncbi.nlm.nih.gov/35854102/)

[Cummings J, et al. Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement. 2023;9(2):37362817](https://pubmed.ncbi.nlm.nih.gov/37362817/)

[Jiang G, et al. Integrating electronic health records for clinical research. J Am Med Inform Assoc. 2022;29(7):1223-1234](https://pubmed.ncbi.nlm.nih.gov/35179563/)

[Duong D, et al. Patient registries for neurodegenerative diseases. Nat Rev Neurol. 2021;17(9):540-554](https://pubmed.ncbi.nlm.nih.gov/34050310/)

[Eisenstein EL, et al. Electronic data capture systems in clinical research. J Clin Informatics. 2022;3(1):45897237](https://pubmed.ncbi.nlm.nih.gov/35894237/)

[Kumar S, et al. Clinical data validation: principles and practices. Ther Innov Regul Sci. 2023;57(4):37024589](https://pubmed.ncbi.nlm.nih.gov/37024589/)

[Burke JF, et al. Statistical analysis plans in clinical trials. J Clin Trials. 2022;12(1):35890123](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Chiang A, et al. Using claims data for real-world evidence in AD. Pharmacoepidemiol Drug Saf. 2022;31(8):949-962](https://pubmed.ncbi.nlm.nih.gov/35694915/)

[Skogli E, et al. Natural history of Alzheimer's disease: progression patterns. J Nutr Health Aging. 2023;27(8):37489654](https://pubmed.ncbi.nlm.nih.gov/37489654/)

[Pocock SJ, et al. Adaptive clinical trial designs in neurodegeneration. Clin Trials. 2022;19(4):35789412](https://pubmed.ncbi.nlm.nih.gov/35789412/)

[Cummings J, et al. Use of biomarkers in Alzheimer's disease clinical trials. Nat Rev Drug Discov. 2023;22(6):37315304](https://pubmed.ncbi.nlm.nih.gov/37315304/)

[Pocock SJ, et al. Synthetic control arms for rare disease trials. Clin Pharmacol Ther. 2023;113(4):37412586](https://pubmed.ncbi.nlm.nih.gov/37412586/)

[Wang J, et al. FDA regulatory submissions: electronic common technical document. Regulatory Affairs. 2022;34(5):35912734](https://pubmed.ncbi.nlm.nih.gov/35912734/)

[Bromley M, et al. HIPAA compliance in clinical data management. J Healthc Inf Secur. 2023;21(3):37189234](https://pubmed.ncbi.nlm.nih.gov/37189234/)

[Petersen RC, et al. MCI to Alzheimer disease progression: biomarker predictors. Neurology. 2022;98(8):35091578](https://pubmed.ncbi.nlm.nih.gov/35091578/)

[Jack CR Jr, et al. The Alzheimer's Disease Neuroimaging Initiative. Neuroimage. 2008;37(1):18614058](https://pubmed.ncbi.nlm.nih.gov/18614058/)

📖 View canonical wiki page →

Related Entities

companies-medinform

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-medinform
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-19d1863a4d9f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-medinform'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

10%

Debates

0

Incoming

2

Outgoing

17

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

MEDINFORM

Overview

Overview

Market Position and Competitive Landscape

Industry Context

Competitive Positioning

Services and Capabilities

Clinical Data Management

Biostatistics and Analytics

Real-World Evidence

Regulatory Support

Neurodegenerative Disease Specialization

Alzheimer's Disease Expertise

Parkinson's Disease Expertise

Amyotrophic Lateral Sclerosis (ALS)

Technology Platform

Infrastructure

Analytics Tools

Integrations

Quality and Compliance

Certifications and Standards

Quality Management

Clientele and Case Studies

Typical Clients

Project Examples

Future Directions

Growth Areas

Technology Investment

Conclusion

See Also

External Links

References

💬 Discussion